Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 6.6% – Still a Buy?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) rose 6.6% on Friday . The stock traded as high as $23.87 and last traded at $23.9650. Approximately 97,131 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 168,102 shares. The stock had previously closed at $22.49.

Wall Street Analyst Weigh In

Several research analysts have commented on NVCT shares. Roth Capital raised their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Loop Capital set a $40.00 price target on shares of Nuvectis Pharma in a report on Tuesday, September 1st. HC Wainwright boosted their price objective on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. UBS Group set a $33.00 target price on shares of Nuvectis Pharma in a report on Monday, July 6th. Finally, Weiss Ratings cut shares of Nuvectis Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.25.

Nuvectis Pharma Stock Performance

The stock has a market cap of $777.65 million, a P/E ratio of -18.33 and a beta of -0.26. The stock has a 50-day moving average price of $20.99 and a 200-day moving average price of $14.29.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Sell-side analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Nuvectis Pharma news, CEO Ron Bentsur bought 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were bought at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the transaction, the chief executive officer directly owned 3,688,424 shares in the company, valued at $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Marlio Charles Mosseri bought 50,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the acquisition, the insider directly owned 3,186,576 shares of the company’s stock, valued at approximately $58,378,072.32. The trade was a 1.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 28.55% of the company’s stock.

Institutional Investors Weigh In On Nuvectis Pharma

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in shares of Nuvectis Pharma by 10.2% during the first quarter. Bank of America Corp DE now owns 14,847 shares of the company’s stock valued at $115,000 after purchasing an additional 1,377 shares in the last quarter. Legal & General Group Plc purchased a new stake in Nuvectis Pharma in the 2nd quarter worth $31,000. California State Teachers Retirement System lifted its position in shares of Nuvectis Pharma by 376.8% in the second quarter. California State Teachers Retirement System now owns 3,991 shares of the company’s stock valued at $73,000 after acquiring an additional 3,154 shares in the last quarter. Barclays PLC boosted its stake in shares of Nuvectis Pharma by 31.3% in the fourth quarter. Barclays PLC now owns 24,185 shares of the company’s stock worth $183,000 after acquiring an additional 5,760 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Nuvectis Pharma by 15.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock worth $332,000 after purchasing an additional 6,040 shares in the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.